Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
60 Results for "
PLPro
" in MedChemExpress (MCE) Product Catalog:
Products (60)
60 Results for "PLPro" in MCE Product Catalog:
Cat. No.: HY-149940
CAS No.: 2708270-99-7
SIMR3030 is a potent SARS-CoV-2 PLpro inhibitor with an IC50 value of 0.0399 µg/mL. SIMR3030 shows antiviral activity. SIMR3030 decreases SARS-CoV spike, ORF1b, IFN-α, IL-6 mRNA expression. SIMR3030 exhibits a satisfactory safety profile in mice .
Cat. No.: HY-168917
CAS No.: 149934-19-0
Synonyms: 9-AMN
Target:
Research Areas:
9-Aminominocycline (9-AMN) is the inhibitor for SARS-CoV-2 papain-like protease (SARS-CoV-2 PLpro), inhibits its deubiquitination (DUB) activity and protease activity with IC50 of 4.55 µM and 4.15 µM. 9-Aminominocycline inhibits the SARS-CoV variants Delta and Omicron replication in Calu-3 cell with IC50 of 1.04 µM and 2.35 µM .
Cat. No.: HY-N0886R
CAS No.: 28371-16-6
Synonyms: Isobarbaloin (Standard)
Cat. No.: HY-179293
Target:
Research Areas:
SARS-CoV-2 PLpro-IN-3 (Compound 15) is a covalent inhibitor of the SARS-CoV-2 papain-like protease (PLpro), with an IC50 of 25 nM. SARS-CoV-2 PLpro-IN-3 has similar inhibitory activity against SARS-CoV PLpro (IC50 = 59 nM), but shows no inhibitory effect on human ubiquitin-specific protease 7 (USP7). The EC50 of SARS-CoV-2 PLpro-IN-3 in inhibiting SARS-CoV-2 replication in cells is 96 nM, significantly reducing the viral titer and viral RNA levels. SARS-CoV-2 PLpro-IN-3 can be used for studying SARS-CoV-2 drug resistance mutations .
Cat. No.: HY-170399
CAS No.: 3053753-61-7
Target:
SARS-CoV-2 PLpro-IN-1 (Compound 85) is a non-covalent and competitive inhibitor of SARS-CoV-2 PLpro with an IC50 of 15.06 μM and a Ki of 22.93 μM. SARS-CoV-2 PLpro-IN-1 inhibits the proliferation of Vero cell with an IC50 of 7.47 μM .
Cat. No.: HY-173305
Target:
Research Areas:
Mpro/PLPro-IN-2 (Compound 22l) is a non-covalent competitive dual inhibitor of the papain-like protease and main protease of SARS-CoV-2, with a Ki of 0.2 μM for the papain-like protease and a Ki of 1.1 μM for the main protease . Mpro/PLPro-IN-2 can be used in the research field of anti-SARS-CoV-2 .
Cat. No.: HY-181641
Target:
Research Areas:
SARS-CoV-2 PLpro-IN-6 is an irreversible SARS-CoV-2 papain-like protease inhibitor with an IC50 value of 0.059 μM. SARS-CoV-2 PLpro-IN-6 exhibits antiviral activity and can be used in studies related to COVID-19 .
Cat. No.: HY-P77831
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: Replicase polyprotein 1a; pp1a; ORF1a polyprotein; Host translation inhibitor nsp1; Leader protein, Non-structural protein 1 (nsp1); Non-structural protein 2 (nsp2); p65 homolog; Papain-like protease nsp3; EC:3.2.2.-; EC:3.4.19.12; EC:3.4.22.-; Non-struct
Species:
Virus
Source:
E. coli
Cat. No.: HY-187197
CAS No.: 3132184-09-6
Target:
Research Areas:
GL-637 is a covalent and selective inhibitor of SARS-CoV-1/2 papain-like protease (PLpro), with IC50 values of 42.4 nM and 50.5 nM against the two viruses, respectively. GL-637 covalently modifies the catalytic Cys111 of PLpro, binds to Glu167 and occupies the BL2 groove, thereby inhibiting the deubiquitinase and deISGylase activities of PLpro. GL-637 can be used in the research of coronaviruses .
Cat. No.: HY-183746
CAS No.: 128232-62-2
Target:
Research Areas:
Catechin-5-O-gallate is a bioactive substance. Catechin-5-O-gallate can be isolated from bioactive Himalayan plants. Catechin-5-O-gallate is predicted to be a P-glycoprotein inhibitor, and binds to SARS-CoV-2 3CLpro, PLpro and RdRp. Catechin-5-O-gallate can be used in studies related to COVID-19 .
Cat. No.: HY-182894
Target:
Research Areas:
MR1-114 is an orally active SARS-CoV-2 papain-like protease (PLpro) inhibitor with an IC50 of 0.037 μM. As a broad-spectrum inhibitor, MR1-114 maintains submicromolar activity against SARS-CoV-2 Delta, Omicron B.1.1.529 and Omicron BA.5 variants, with EC50 values of 0.18 μM, 0.39 μM and 0.20 μM, respectively. MR1-114 can be used for the research of coronavirus disease 2019 (SARS-CoV-2 infection) .
Cat. No.: HY-W653745
CAS No.: 1330266-29-9
Synonyms: Thioguanine-13C2,15N; 2-Amino-6-purinethiol-13C2,15N
Cat. No.: HY-182428
CAS No.: 2589736-94-5
UAWJ248 is a SARS-CoV-2 main protease (M pro) inhibitor with an IC50 of 0.012 μM. UAWJ248 inhibits activity via initial reversible binding followed by irreversible inactivation. UAWJ248 inhibits SARS-CoV-2 replication and can be used for the research of SARS-CoV-2 infection .
Cat. No.: HY-181661
Target:
Research Areas:
YL1004 is a potent, selective and orally active noncovalent inhibitor of SARS-CoV-2 papain-like protease (PL pro). YL1004 shows an IC50 of 17.5 nM and a Ki of 2.3 nM against PL pro, with an in vitro anti-SARS-CoV-2 EC50 of 0.08 μM-1.37 μM. YL1004 suppresses the proteolytic activity of PL pro and blocks its deubiquitinating and deISGylating effects to restore host innate antiviral immune signaling. YL1004 inhibits the replication of wild-type, Delta, Omicron variants and nirmatrelvir-resistant strains of SARS-CoV-2. YL1004 can be used for the research of COVID-19 (SARS-CoV-2 infection) .
Cat. No.: HY-L052
1,380 compounds
COVID-19 poses a serious threat to people's health, and it is urgent to develop drugs to treat COVID-19 quickly. The screening of anti-COVID-19 drugs by using the clinical and approved compounds can greatly shorten the research and development cycle. In addition, the virtual screening technology can effectively narrow the scope of screening and improve the screening efficiency in the pre-screening of new drugs.
Taking advantage of our virtual screening, we conduct virtual screening of approved compound library and clinical compound library based on the 3CL protease (PDB ID: 6LU7), Spike Glycoprotein (PDB ID: 6VSB), NSP15 (PDB ID: 6VWW), RDRP, PLPro and ACE2 (Angiotensin Converting Enzyme 2) structure. We design a unique collection of 1,380 compounds which may have anti-COVID-19 activity. Anti-COVID-19 Compound Library will be a powerful tool for screening new anti-COVID-19 activity drugs.
Cat. No.: HY-P702190
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Replicase polyprotein 1a; pp1a; ORF1a polyprotein; Host translation inhibitor nsp1; Leader protein, Non-structural protein 1 (nsp1); Non-structural protein 2 (nsp2); p65 homolog; Papain-like protease nsp3; EC:3.2.2.-; EC:3.4.19.12; EC:3.4.22.-; Non-struct
Species:
Virus
Source:
E. coli
Cat. No.: HY-P703548
Purity: ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: Replicase polyprotein 1a; pp1a; ORF1a polyprotein; Non-structural protein 2 (nsp2); p87; Papain-like protease nsp3 (PL-PRO) (EC:3.2.2.-, EC:3.4.19.12, EC:3.4.22.-); Non-structural protein 3 (nsp3) ; p195; Non-structural protein 4 (nsp4); Peptide HD2, p41;
Species:
Virus
Source:
E. coli
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
